FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Arcutis Biotherapeutics, Inc. Stock AnalysisComprehensive stock analysis for Arcutis Biotherapeutics, Inc. (ARQT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisARQT
ARQT
Arcutis Biotherapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ARQT
Home🔹Stocks🔹Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT•NASDAQ

Arcutis Biotherapeutics, Inc.

ARQT•NASDAQ
Market cap
$3.55B
Sentiment

Your view on ARQT

Mkt Cap
$3.55B
Sentiment
Your view
ARQT
Arcutis Biotherapeutics, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ARQT
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Arcutis Biotherapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Todd Franklin Watanabe
Headquarters
3027 Townsgate Road, Westlake Village, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Todd Franklin Watanabe
Headquarters
3027 Townsgate Road, Westlake Village, CA, US
Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News